Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related...

Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA

GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for diabetics ( Dr Lucas A Mavromatis - NYU Grossman School of Medicine, New York, USA )

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

Rusfertide shows promise for polycythemia vera treatment

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Rusfertide shows promise for polycythemia vera treatment ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy...

Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise ( Dr Lajos Pusztai - Yale School of Medicine, New Haven, USA )

Darolutamide plus ADT provides deep and durable PSA responses in metastatic...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive...

Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer ( Dr Sindhuja Kadambi - University of Rochester Medical Center, Rochester, USA )

Talazoparib and enzalutamide combination therapy shows significant benefit in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Everolimus plus lanreotide might be a new standard treatment in the first-line...

Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs ( Dr Susumu Hijioka - National Cancer Center Hospital, Chuo City, Japan )

Targeted therapies associated with increased risk for and incidence of...

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron...

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar...

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona...

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz

EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )

More from ecancer